Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study
Jiayou Zhang(Wuhan Institute of Bioengineering), Xiaoming Yang(Shanghai Municipal Center For Disease Control Prevention), Kai Duan(University Health Network), Xuedan Li(Wuhan University), Zheng Gong(Fudan University), Xixin Han(Wuhan Institute of Bioengineering), Xuanxuan Nian(Wuhan Institute of Bioengineering), Zhegang Zhang(Wuhan Institute of Bioengineering), Wei Zhao(Anhui Medical University), Fang Li(China Pharmaceutical University), Bo Liu(China Agricultural University), Hua Ma, Yumei Ma, Xinguo Li(Wuhan Institute of Bioengineering), Li Zhou(Wuhan University), Ran Qiu(Wuhan Institute of Bioengineering), Zhongren Ma, Ying Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qingmei Zhang(University of Hong Kong - Shenzhen Hospital), Dongwu Jin
Cited by 11
Related Papers
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
|JAMA|2021|829
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
|JAMA|2020|805
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
Nuclear lactate dehydrogenase A senses ROS to produce α-hydroxybutyrate for HPV-induced cervical tumor growth
|Nature Communications|2018|166